# REVA Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reva-medical

- Industry: Medical Devices & Equipment
- Headquarters: San Diego, US
- Website: www.revamedical.com
- Total disclosed funding: $87M
- Latest round: Series B (Aug 8, 2022)
- Investors on record: 6

## About

REVA Medical, LLC specializes in developing innovative bioresorbable polymer technologies for vascular applications, creating implantable medical devices aimed at improving treatment outcomes for patients with hypervascular tumors.Founded in 1998 in San Diego, California, REVA Medical, LLC focuses on the development of medical devices utilizing bioresorbable technologies. The company has undergone strategic changes to refine its focus on vascular applications. As of December 2010, REVA Medical successfully closed a SERIES B funding round, raising USD 45.00 mn, which contributed to its total funds raised of USD 45.00 mn. The current CEO is Jeff Anderson, who has a robust background in medical technology entrepreneurship.REVA Medical specializes in the development of bioresorbable polymer technologies designed for vascular applications, primarily focusing on the creation of implantable medical devices. The company's core product, TyroSphere beads, are bioresorbable embolic microspheres specifically engineered for the treatment of hypervascular tumors. These microspheres are notable for their unique properties that include safe degradation and radiopacity, allowing for visibility under standard X-ray imaging. This visibility aids medical professionals in the precise delivery of the beads to targeted tumor sites, enhancing treatment effectiveness. REVA Medical targets a diverse client base, including hospitals, medical practitioners, and healthcare providers across North America and Europe, where advanced vascular therapies are in high demand.REVA Medical generated revenue of USD 45,000 in 2017, with an EBITDA of USD -20,267,000. The company's revenue generation primarily stems from the sale of its implantable medical devices, particularly the TyroSphere beads, through B2B transactions with healthcare providers and hospitals that require specialized devices for patient treatment. Revenue is derived from direct sales, structured as bulk purchases for clinical use, reflecting the complexity and innovation of the devices offered.Looking ahead, REVA Medical aims to expand its product offerings and enter new markets. The company has plans for new product launches in the coming years, although specific release dates have not been disclosed. Following the completion of its IPO in December 2010, which raised USD 85 mn, REVA Medical intends to utilize this funding to support its growth initiatives, including the enhancement of its manufacturing capabilities and the expansion of its market presence in North America and Europe. These strategies are expected to significantly facilitate the company's future development and market penetration.

## Funding rounds

- Series B, Aug 8, 2022, $45M — BioStar Capital
- Series H, Dec 10, 2007, $42M — Cerberus Capital Management, Domain Associates, Brookside Capital Partners, Medtronic, FirstMark Capital

## Investors

- Cerberus Capital Management (https://capitalatlas.ai/funds/cerberus-capital-management) — Series H
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series H
- Brookside Capital Partners (https://capitalatlas.ai/funds/brookside-capital-partners) — Series H
- Medtronic — Series H
- FirstMark Capital (https://capitalatlas.ai/funds/firstmark-capital) — Series H
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series B